Puma Biotechnology (PBYI)
Commercializes NERLYNX for HER2-positive breast cancer and develops alisertib.
$9.69
Pre-market−0.01 (−0.05%)
At close$9.70(+3.69%)
Something off on this page? Send us feedback.
Next report
Nov 5, 2026
in 63 days
EPS estimate
$0.11
Revenue estimate
$57.5M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$0.43$0.10$0.15$0.21$0.29−$0.04$0.19Pending
Estimate$0.10$0.02$0.11$0.09$0.24−$0.13$0.04$0.11
Surprise+330.0%+400.0%+36.4%+133.3%+20.8%+69.2%+375.0%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$59.1M$46.0M$52.4M$54.5M$59.9M$44.8M$56.5MPending
Estimate$52.5M$52.8M$51.0M$68.6M$68.6M$42.0M$53.0M$57.5M
Surprise+12.5%−12.8%+2.8%−20.6%−12.7%+6.7%+6.6%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | $0.11 | — | — |
| Aug 2026 | $0.04 | $0.19 | +375.0% |
| May 2026 | −$0.13 | −$0.04 | +69.2% |
| Feb 2026 | $0.24 | $0.29 | +20.8% |
| Nov 2025 | $0.09 | $0.21 | +133.3% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | $0.11 | — | — | $57.5M | — | — | — |
| Aug 6, 2026 | $0.04 | $0.19 | +375.0% | $53.0M | $56.5M | +6.6% | +9.7% |
| May 7, 2026 | −$0.13 | −$0.04 | +69.2% | $42.0M | $44.8M | +6.7% | +3.2% |
| Feb 26, 2026 | $0.24 | $0.29 | +20.8% | $68.6M | $59.9M | −12.7% | −25.0% |
| Nov 6, 2025 | $0.09 | $0.21 | +133.3% | $68.6M | $54.5M | −20.6% | +22.2% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Aug 7, 2025 | |||||||
| May 8, 2025 | |||||||
| Feb 27, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 1, 2024 | |||||||
| May 2, 2024 | |||||||
| Feb 29, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 4, 2023 | |||||||
| Mar 2, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Mar 3, 2022 | |||||||
| Nov 4, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Feb 25, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 7, 2020 | |||||||
| Feb 20, 2020 | |||||||
| Nov 6, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 9, 2019 | |||||||
| Feb 28, 2019 | |||||||
| Nov 1, 2018 | |||||||
| Aug 9, 2018 | |||||||
| May 9, 2018 | |||||||
| Mar 1, 2018 | |||||||
| Nov 9, 2017 | |||||||
| Aug 9, 2017 | |||||||
| May 10, 2017 | |||||||
| Mar 1, 2017 | |||||||
| Nov 9, 2016 | |||||||
| Aug 9, 2016 | |||||||
| May 10, 2016 | |||||||
| Feb 29, 2016 | |||||||
| Nov 9, 2015 | |||||||
| Aug 10, 2015 | |||||||